How should we use calcineurin inhibitors in myasthenia gravis?

Hiroyuki Murai

doi:10.1111/cen3.12206

How should we use calcineurin inhibitors in myasthenia gravis?

Hiroyuki Murai

医学研究院

研究成果: Contribution to journal › Review article › 査読

抄録

Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.

本文言語	英語
ページ（範囲）	118-119
ページ数	2
ジャーナル	Clinical and Experimental Neuroimmunology
巻	6
号	2
DOI	https://doi.org/10.1111/cen3.12206
出版ステータス	出版済み - 5 1 2015

All Science Journal Classification (ASJC) codes

Neuroscience (miscellaneous)
Immunology
Immunology and Microbiology (miscellaneous)
Clinical Neurology

文献へのアクセス

10.1111/cen3.12206

他のファイルとリンク

フィンガープリント「How should we use calcineurin inhibitors in myasthenia gravis?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{4e73b514cc0a4f01808307d84a5f25f2,

title = "How should we use calcineurin inhibitors in myasthenia gravis?",

abstract = "Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.",

author = "Hiroyuki Murai",

year = "2015",

month = may,

day = "1",

doi = "10.1111/cen3.12206",

language = "English",

volume = "6",

pages = "118--119",

journal = "Clinical and Experimental Neuroimmunology",

issn = "1759-1961",